Q-omics provides the consensus-scored SLC36A4 profile across patient tissues and cancer cell-line models. SLC36A4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SLC36A4 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, SLC36A4 RNA expression shows 19,684 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where SLC36A4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC36A4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC36A4 survival associations across molecular data types. SLC36A4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC36A4 RNA expression–survival associations across cancer types. High SLC36A4 expression shows unfavorable associations in ACC, UVM, KICH and LGG, but favorable associations in COAD and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SLC36A4 RNA expression.
This table summarizes SLC36A4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SLC36A4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC36A4 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LUAD, KIRP and LIHC. The HNSC box plot shows higher SLC36A4 RNA expression in tumor versus normal tissue (log2 FC = +0.815, t-test p < 0.001).
This table shows molecular features associated with SLC36A4 in patient tissues and cancer cell lines. In patient samples, SLC36A4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC36A4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
